The landscape of dementia prognosis has evolved radically with the advent of innovative biomarkers, together with amyloid PET scans, tau imaging, and blood-primarily based exams that could detect Alzheimer's pathology decades before signs emerge. Although these technological advancements characterize remarkable progress in comprehending neurodegene